Metagenomi Shifts Focus from ALS to Kidney Disease, Seeks New Partners

Metagenomi Drops ALS Program:
Metagenomi has decided to discontinue its ALS program and is now focusing on kidney disease research and development.

Search for New Kidney Disease Partner:
The company is actively seeking a new partner to collaborate on kidney disease research and development initiatives.

Regained Development Rights:
Metagenomi has regained full global rights to develop its gene editing technologies, including base editors and RNA-mediated integration systems (RIGS), which were previously under an exclusive agreement with Moderna.

Strategic Flexibility:
This move enhances Metagenomi's strategic flexibility and control over its gene editing technologies, allowing the company to advance these technologies in areas such as Alpha-1 antitrypsin deficiency and Wilson’s disease.

Internal Capabilities:
Metagenomi has built significant internal capabilities and expertise to advance its programs, leveraging both private and public funding to expand its gene editing toolbox and establish in-house manufacturing.

Medicare Coverage for Kidney Disease:
Individuals with end-stage renal disease (ESRD) are eligible for Medicare regardless of age, provided they meet specific criteria related to dialysis or kidney transplantation.

Chronic Kidney Disease (CKD) Rise:
CKD is on the rise, primarily due to increasing rates of diabetes and high blood pressure. Early detection and treatment can help slow the progression of CKD.

Historical Context of Medicare Coverage:
The Medicare entitlement for chronic kidney failure patients was established in 1972, following significant advancements in hemodialysis and kidney transplantation in the preceding decades.